Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Grivas

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Hematology/Oncology Clinics of North America|November 3, 2012
Urethral cancerPetros D Grivas, Matthew Davenport, James E Montie, et al.
European Journal of Cancer (Oxford, England : 1990)|October 9, 2007
HER-3 in colorectal tumourigenesis: from mRNA levels through protein status to clinicopathologic relationshipsPetros D Grivas, Anna Antonacopoulou, Vassiliki Tzelepi, et al.
Journal of Neuro-Oncology|July 8, 2011
Prognostic value of novel biomarkers in astrocytic brain tumors: nuclear receptor co-regulators AIB1, TIF2, and PELP1 are associated with high tumor grade and worse patient prognosisZinovia Kefalopoulou, Vassiliki Tzelepi, Vassiliki Zolota, et al.
Molecular Medicine (Cambridge, Mass.)|October 30, 2013
Evaluation of the antitumor activity of dacomitinib in models of human bladder cancerPetros D Grivas, Kathleen C Day, Andreas Karatsinides, et al.
Urology|May 28, 2013
A phase II trial of neoadjuvant nab-paclitaxel, carboplatin, and gemcitabine (ACaG) in patients with locally advanced carcinoma of the bladderPetros D Grivas, Maha Hussain, Khaled Hafez, et al.
World Journal of Urology|August 20, 2015
Clinical and therapeutic factors associated with adverse pathological outcomes in clinically node-negative patients treated with neoadjuvant cisplatin-based chemotherapy and radical cystectomyKamran Zargar-Shoshtari, Homayoun Zargar, Colin P Dinney, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|April 9, 2016
Low-Cost Intervention to Increase Influenza Vaccination Rate at a Comprehensive Cancer CenterPetros D Grivas, Sumana Devata, Rami Khoriaty, et al.
Cancer|November 20, 2013
Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinomaPetros D Grivas, Stephanie Daignault, Scott T Tagawa, et al.
Urologic Oncology|March 3, 2018
Recommendations for follow-up of muscle-invasive bladder cancer patients: A consensus by the international bladder cancer networkTahlita C M Zuiverloon, Kim E M van Kessel, Trinity J Bivalacqua, et al.
Cancer|May 8, 2014
A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinomaMaha Hussain, Stephanie Daignault, Neeraj Agarwal, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Hematology/Oncology Clinics of North America|November 3, 2012
Urethral cancerPetros D Grivas, Matthew Davenport, James E Montie, et al.
European Journal of Cancer (Oxford, England : 1990)|October 9, 2007
HER-3 in colorectal tumourigenesis: from mRNA levels through protein status to clinicopathologic relationshipsPetros D Grivas, Anna Antonacopoulou, Vassiliki Tzelepi, et al.
Journal of Neuro-Oncology|July 8, 2011
Prognostic value of novel biomarkers in astrocytic brain tumors: nuclear receptor co-regulators AIB1, TIF2, and PELP1 are associated with high tumor grade and worse patient prognosisZinovia Kefalopoulou, Vassiliki Tzelepi, Vassiliki Zolota, et al.
Molecular Medicine (Cambridge, Mass.)|October 30, 2013
Evaluation of the antitumor activity of dacomitinib in models of human bladder cancerPetros D Grivas, Kathleen C Day, Andreas Karatsinides, et al.
Urology|May 28, 2013
A phase II trial of neoadjuvant nab-paclitaxel, carboplatin, and gemcitabine (ACaG) in patients with locally advanced carcinoma of the bladderPetros D Grivas, Maha Hussain, Khaled Hafez, et al.
World Journal of Urology|August 20, 2015
Clinical and therapeutic factors associated with adverse pathological outcomes in clinically node-negative patients treated with neoadjuvant cisplatin-based chemotherapy and radical cystectomyKamran Zargar-Shoshtari, Homayoun Zargar, Colin P Dinney, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|April 9, 2016
Low-Cost Intervention to Increase Influenza Vaccination Rate at a Comprehensive Cancer CenterPetros D Grivas, Sumana Devata, Rami Khoriaty, et al.
Cancer|November 20, 2013
Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinomaPetros D Grivas, Stephanie Daignault, Scott T Tagawa, et al.
Urologic Oncology|March 3, 2018
Recommendations for follow-up of muscle-invasive bladder cancer patients: A consensus by the international bladder cancer networkTahlita C M Zuiverloon, Kim E M van Kessel, Trinity J Bivalacqua, et al.
Cancer|May 8, 2014
A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinomaMaha Hussain, Stephanie Daignault, Neeraj Agarwal, et al.
Pageof 4